COSCIENS BIOPHARMA INC (CSCI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CSCI • CA22112H1010

2.72 USD
-0.36 (-11.69%)
At close: Sep 3, 2025
2.59 USD
-0.13 (-4.78%)
After Hours: 9/3/2025, 8:07:43 PM
Fundamental Rating

2

CSCI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. CSCI may be in some trouble as it scores bad on both profitability and health. CSCI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CSCI has reported negative net income.
  • CSCI had a negative operating cash flow in the past year.
  • In the past 5 years CSCI always reported negative net income.
  • In the past 5 years CSCI always reported negative operating cash flow.
CSCI Yearly Net Income VS EBIT VS OCF VS FCFCSCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

  • CSCI has a Return On Assets (-56.40%) which is in line with its industry peers.
  • The Return On Equity of CSCI (-173.14%) is worse than 64.39% of its industry peers.
Industry RankSector Rank
ROA -56.4%
ROE -173.14%
ROIC N/A
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
CSCI Yearly ROA, ROE, ROICCSCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

  • CSCI has a better Gross Margin (47.26%) than 75.09% of its industry peers.
  • In the last couple of years the Gross Margin of CSCI has grown nicely.
  • CSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
CSCI Yearly Profit, Operating, Gross MarginsCSCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

  • CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CSCI has been increased compared to 1 year ago.
  • CSCI has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CSCI has an improved debt to assets ratio.
CSCI Yearly Shares OutstandingCSCI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
CSCI Yearly Total Debt VS Total AssetsCSCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -1.29, we must say that CSCI is in the distress zone and has some risk of bankruptcy.
  • CSCI has a Altman-Z score of -1.29. This is comparable to the rest of the industry: CSCI outperforms 56.09% of its industry peers.
  • A Debt/Equity ratio of 0.19 indicates that CSCI is not too dependend on debt financing.
  • CSCI's Debt to Equity ratio of 0.19 is on the low side compared to the rest of the industry. CSCI is outperformed by 68.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -1.29
ROIC/WACCN/A
WACC8.9%
CSCI Yearly LT Debt VS Equity VS FCFCSCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 2.88 indicates that CSCI has no problem at all paying its short term obligations.
  • The Current ratio of CSCI (2.88) is worse than 64.94% of its industry peers.
  • A Quick Ratio of 2.54 indicates that CSCI has no problem at all paying its short term obligations.
  • CSCI has a worse Quick ratio (2.54) than 66.97% of its industry peers.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.54
CSCI Yearly Current Assets VS Current LiabilitesCSCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 13.07% over the past year.
  • The Revenue has grown by 103.93% in the past year. This is a very strong growth!
  • CSCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 80.53% yearly.
EPS 1Y (TTM)13.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.45%
Revenue 1Y (TTM)103.93%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%-27.08%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CSCI Yearly Revenue VS EstimatesCSCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CSCI Yearly EPS VS EstimatesCSCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • CSCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSCI Price Earnings VS Forward Price EarningsCSCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSCI Per share dataCSCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • CSCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COSCIENS BIOPHARMA INC

NASDAQ:CSCI (9/3/2025, 8:07:43 PM)

After market: 2.59 -0.13 (-4.78%)

2.72

-0.36 (-11.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11
Earnings (Next)11-10
Inst Owners9.04%
Inst Owner Change-89.54%
Ins Owners1.49%
Ins Owner ChangeN/A
Market Cap8.65M
Revenue(TTM)9.03M
Net Income(TTM)-17.56M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.96
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 0.85
EV/EBITDA N/A
EPS(TTM)-5.8
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.38
FCFYN/A
OCF(TTM)-3.82
OCFYN/A
SpS2.84
BVpS3.19
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.4%
ROE -173.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.26%
FCFM N/A
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
F-Score2
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.8%
Cap/Sales 19.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.54
Altman-Z -1.29
F-Score2
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)43.14%
Cap/Depr(5y)N/A
Cap/Sales(3y)7.47%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)103.93%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%-27.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.32%
OCF growth 3YN/A
OCF growth 5YN/A

COSCIENS BIOPHARMA INC / CSCI FAQ

What is the fundamental rating for CSCI stock?

ChartMill assigns a fundamental rating of 2 / 10 to CSCI.


What is the valuation status for CSCI stock?

ChartMill assigns a valuation rating of 0 / 10 to COSCIENS BIOPHARMA INC (CSCI). This can be considered as Overvalued.


How profitable is COSCIENS BIOPHARMA INC (CSCI) stock?

COSCIENS BIOPHARMA INC (CSCI) has a profitability rating of 1 / 10.